Assembly Biosciences stock
ASMBNASDAQAssembly Biosciences, Inc., HealthcareISIN US0453962070
33Score 33 out of 100, Weak
Price and trend
42 / 100
Price history
−44% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 25% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 48% below its 52-week high. Largest decline in 16 years: 99% (May 2011 to November 2023).
Chart figures for advanced users
- SMA 50$23.55
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.88
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.51
- The lowest closing price of the last twelve months.
- Resistance$38.50
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Assembly Biosciences, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $410.88M, is number 252 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $72.3M (up 153.5% year on year) and a loss of $6.12M.
- MEQIRI Score 33 out of 100 (Weak): rank 657 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $320.36M, financial debt $2.35M.Stability 72
Weaknesses
- DilutionShare count up 183% since 2020.Capital allocation 18
- Loss-makingLoss of $42K over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$38.57M over the last 12 months.Fundamentals 17
Its standout strength is stability, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 32 to 33.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 125% on the twelve months before. Revenue has grown strongly since 2023, at around 218% per year. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −17%, net −8%. Last 12 months: net 0%. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Mar 2027in 133 days
- Last reported
- 12 Nov 2026EPS reported −$0.93 (expected −$0.66)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.610.0%
- Revenue
- $63.43M0.0%
- Earnings per share
- −$3.050.0%
- Revenue
- $42.65M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $238,322 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Assembly Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Oculis HoldingOCS $469.78M30
- BlossomHill TherapeuticsBLSM $468.79M43
- CytomX TherapeuticsCTMX $464.35M31
- Hansa BiopharmaHNSA.ST $458.62M47
- ArvinasARVN $452.5M37
- AgenusAGEN $452.32M49
- Gyre TherapeuticsGYRE $451.7M35
- ProthenaPRTA $448.28M43
ETFs that hold Assembly Biosciences
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Dec 2011)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.